Company intelligence / Profile preview

Sensei Biotherapeutics

Rockville, Maryland, United Statessenseibio.com ↗

Ownership: Public · SNSE
Development stage: Phase 1

Overview

Sensei's lead product candidate solnerstotug (SNS-101) has shown promising clinical activity in a Phase 1/2 trial with a favorable safety profile. The drug targets VISTA selectively within the low pH tumor microenvironment. The company has completed target enrollment (n=60) in the dose expansion cohort with full expansion data expected by year-end 2025[5][9].

Therapeutic areas: Oncology
Modalities: Monoclonal antibodiesconditionally active antibodiesbacteriophage-based immunotherapies
Industry: Biotech

Drug pipeline

13 assets

serabelisib

12 more assets in the full pipeline.

Request access →

Partnerships

Regeneron PharmaceuticalsNational Cancer Institute (NCI)

Financials

Market cap: $18.6M
Total revenue: $0
Enterprise value: $-167.3M

Beyond the preview

Go deeper on Sensei Biotherapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sensei Biotherapeutics.

Explore the full profile